NovoCure (NVCR) Return on Equity (2015 - 2026)

NovoCure's Return on Equity history runs 12 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Equity changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at NovoCure, down from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2022 to a low of 0.01% in Q4 2023.
• A 5-year average of 0.0% and a median of 0.0% in 2025 frame the typical range for Return on Equity.
• On a YoY basis, Return on Equity climbed as much as 0 bps in 2022 and fell as far as 0 bps in 2022.
• NovoCure's Return on Equity stood at 0.0% in 2022, then tumbled by 162 bps to 0.01% in 2023, then grew by 15 bps to 0.0% in 2024, then gained by 15 bps to 0.0% in 2025, then declined by 29 bps to 0.01% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.01%, 0.0%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison